Palabiyik Ahmet Alperen, Palabiyik Esra
Faculty of Health Sciences, Department of Nursing, Ardahan University, Ardahan, Türkiye.
Department of Molecular Biology and Genetics, Department of Genetics, Atatürk University, Erzurum, Türkiye.
Mol Biol Rep. 2025 Feb 28;52(1):270. doi: 10.1007/s11033-025-10368-8.
Mitochondrial biogenesis is essential for cellular energy balance and metabolic stability. Its dysregulation is linked to various metabolic and neurodegenerative diseases, making it a significant therapeutic target. Pharmacological approaches aimed at enhancing mitochondrial function have gained attention for their potential to restore cellular metabolism.
This review examines recent advancements in pharmacological strategies targeting mitochondrial biogenesis, focusing on the roles of PGC-1α, AMPK, and SIRT1, alongside novel therapeutic agents and drug delivery systems.
A systematic review of studies published between 2018 and 2023 was conducted using databases such as PubMed, Web of Science, and Elsevier. Keywords related to mitochondrial biogenesis and pharmacological modulation were used to identify relevant literature.
Various pharmacological agents, including resveratrol, curcumin, and metformin, activate mitochondrial biogenesis through different pathways. SIRT1 activators and AMPK agonists have shown promise in improving mitochondrial function. Advances in mitochondria-targeted drug delivery systems enhance therapeutic efficacy, yet challenges remain in clinical translation due to the complexity of mitochondrial regulation.
Pharmacological modulation of mitochondrial biogenesis holds therapeutic potential for metabolic and neurodegenerative diseases. While preclinical studies are promising, further research is needed to optimize drug efficacy, delivery methods, and personalized treatment strategies.
线粒体生物发生对于细胞能量平衡和代谢稳定性至关重要。其失调与多种代谢和神经退行性疾病相关，使其成为一个重要的治疗靶点。旨在增强线粒体功能的药理学方法因其恢复细胞代谢的潜力而受到关注。
本综述探讨了针对线粒体生物发生的药理学策略的最新进展，重点关注过氧化物酶体增殖物激活受体γ共激活因子1α（PGC-1α）、腺苷酸活化蛋白激酶（AMPK）和沉默信息调节因子1（SIRT1）的作用，以及新型治疗药物和药物递送系统。
使用PubMed、科学网和爱思唯尔等数据库对2018年至2023年间发表的研究进行系统综述。使用与线粒体生物发生和药理学调节相关的关键词来确定相关文献。
包括白藜芦醇、姜黄素和二甲双胍在内的各种药理学药物通过不同途径激活线粒体生物发生。SIRT1激活剂和AMPK激动剂在改善线粒体功能方面显示出前景。线粒体靶向药物递送系统的进展提高了治疗效果，但由于线粒体调节的复杂性，临床转化仍面临挑战。
线粒体生物发生的药理学调节对代谢和神经退行性疾病具有治疗潜力。虽然临床前研究很有前景，但仍需要进一步研究来优化药物疗效、递送方法和个性化治疗策略。
